Dutch Biotech takes RSV vaccine nasal spray vaccine into Ph I trial

By Dani Bancroft

- Last updated on GMT

iStock/RusN
iStock/RusN

Related tags: Antibody, Immune system

Mucosis B.V. has started a volunteer study of SynGEM, a respiratory syncytial virus (RSV) vaccine formulated for nasal delivery.

The UK-based study Phase I study - which is part funded by a grant from the Wellcome Trust​ – is designed to assess both SynGEM and the nasal delivery device - Teleflex VaxINator – in a real world setting according to Mucosis CEO, Tom Johnston.

Mucosis developed SynGEM using its proprietary probiotics-based technology, Mimopath. The vaccine consists of a pre-fusion version of an RSV antigen formulated for intranasal delivery.

Formulation development was a complex process according to Johnston, who said: “One of the challenges with pre-fusion F antigens has been its natural lack of stability.  Mucosis was able to engineer around this to create a stable antigen and patent this design​.”

The firm claims pre-fusion RSV antigens produced using the Mimopath technology stimulate production of antibodies against the virus more effectively than post-fusion versions of the same protein.

Why Needle-Free

The Teleflex VaxINator Intranasal Mucosal Atomisation Device (MAD) uses pressure to aerosolize the vaccine as a ‘fine mist’ that can be delivered to the nasal passageways directly.

Studies​ have shown that introducing RSV antibodies via the mucous membranes generates a better systemic immune response.

In addition, the research also demonstrated that a raised antibody response in the mucous membranes helps block entry of the virus, thereby providing an effective first-line of defence.

This has prompted several other companies to pursue intranasal products – such as AstraZeneca’s nasal flu spray​, Fluenz Tetra, or the Belgian biotech Ablynx’s therapy for RSV, due to start a Phase IIb efficacy study later this year.

Similarly, Ablynx’s nanobody product ALX-0171 – which is a post infection RSV antiviral therapy - has also been formulated for intranasal delivery.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us

Products

View more

Webinars